Bionano Genomics, Inc. BNGO
At closeNov 5, 2026, 4:41 AM EST
Pre-market · Nov 5, 4:41 AM ET
- YTD
- -22.22%
- 1 year
- -29.59%
- Market cap
- 16.63M
- Revenue (ttm)
- 36.58M
- EPS (ttm)
- -3.02
- Shares out
- 101.99M
- Forward P/E
- -0.41
- YTD return
- -22.22%
- 1-year return
- -29.59%
- Volume
- 72.14K
- Avg volume
- 942.10K
- Open
- 1.21
- Previous close
- 1.20
- Day's range
- 1.18 – 1.22
- 52-week range
- 1.00 – 2.23
- Beta
- 2.38
- Price target
- 1.00 (-16.0%)
- Earnings date
- Aug 7, 2024
30m -0.01 (-0.83%)
Key statistics
- Enterprise value
- 30.64M
- PEG ratio
- 0.00
- Price / sales
- 0.56
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -10.30%
- Free cash flow
- -55.98M
- Total cash
- 18.94M
- Total debt
- 27.57M
- Return on equity
- -138.33%
- Short % of float
- 10.26%
- 50-day average
- 0.2652
- 200-day average
- 0.6133
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.32 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -0.24 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -0.60 | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | -0.96 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Ladenburg Thalmann | down | Buy | Neutral |
| May 16, 2024 | BTIG | main | Buy | Buy |
| Mar 7, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 13, 2023 | Maxim Group | down | Buy | Hold |
| Aug 10, 2023 | BTIG | main | Buy | Buy |
About Bionano Genomics, Inc.
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- bionano.com
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Bionano Genomics Stock Surges Tuesday: What's Going On?
12 Health Care Stocks Moving In Tuesday's Intraday Session Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate
Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est
Earnings Scheduled For May 13, 2026
Your note
Sign in to keep a note on BNGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAUBEY ALKA PH.D. | Officer | Stock Award(Grant) | Jun 2, 2024 | 48,245 |
| DIXON JONATHAN V | General Counsel | Stock Award(Grant) | Jun 2, 2024 | 18,025 |
| HOLMLIN R ERIK | Chief Executive Officer | Stock Award(Grant) | Jun 2, 2024 | 122,315 |
| KAMA GULSEN | Chief Financial Officer | Stock Award(Grant) | Jun 2, 2024 | 16,000 |
| MAMUSZKA HANNAH | Director | Purchase | Jun 12, 2023 | 65,789 |
| OLDAKOWSKI MARK | Chief Operating Officer | Stock Award(Grant) | Jun 2, 2024 | 64,698 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.15% | 2,192,492 | 443.76K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 882,854 | 178.69K | Sep 29, 2024 |
| Blackrock Inc. | 0.60% | 614,163 | 124.31K | Sep 29, 2024 |
| GMT Capital Corp | 0.52% | 530,260 | 107.32K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.24% | 249,070 | 50.41K | Sep 29, 2024 |
| Northern Trust Corporation | 0.14% | 147,134 | 29.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.34% | 1,364,438 | 276.16K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.50% | 505,292 | 102.27K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 492,060 | 99.59K | Oct 30, 2024 |
| Vanguard Health Care Index Fund | 0.20% | 208,601 | 42.22K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 166,234 | 33.65K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 116,331 | 23.55K | Oct 30, 2024 |
